Starpharma Holdings Limited (SPL.AX)
AUD 0.1
(0.0%)
AUD 0.1
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -12.57 Million AUD | 36.83% |
| 2023 | -15.24 Million AUD | -2.91% |
| 2022 | -15.79 Million AUD | 17.73% |
| 2021 | -21.42 Million AUD | -35.17% |
| 2020 | -14.4 Million AUD | -47.02% |
| 2019 | -13.95 Million AUD | -39.92% |
| 2018 | -11.43 Million AUD | 33.06% |
| 2017 | -14.89 Million AUD | 26.82% |
| 2016 | -21.74 Million AUD | -14.87% |
| 2015 | -17.72 Million AUD | -30.98% |
| 2014 | -13.53 Million AUD | -224.51% |
| 2013 | -4.17 Million AUD | 66.66% |
| 2012 | -12.5 Million AUD | -69.44% |
| 2011 | -7.38 Million AUD | -58.21% |
| 2010 | -4.66 Million AUD | -105.19% |
| 2009 | -2.27 Million AUD | 71.99% |
| 2008 | -6.09 Million AUD | -2.33% |
| 2007 | -5.91 Million AUD | -21.43% |
| 2006 | -5.89 Million AUD | 5.08% |
| 2005 | -7.8 Million AUD | -40.98% |
| 2004 | -6.65 Million AUD | 29.49% |
| 2003 | -6.92 Million AUD | 23.74% |
| 2002 | -8.69 Million AUD | -64.45% |
| 2001 | -5.52 Million AUD | -55.79% |
| 2000 | -3.54 Million AUD | -51.56% |
| 1999 | -2.33 Million AUD | 8.0% |
| 1998 | -2.54 Million AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -4.38 Million AUD | 0.0% |
| 2024 Q4 | -6.98 Million AUD | 0.0% |
| 2024 FY | - AUD | 40.19% |
| 2023 Q2 | -12.59 Million AUD | 0.0% |
| 2023 FY | - AUD | -2.91% |
| 2023 Q4 | -10.88 Million AUD | 0.0% |
| 2022 FY | - AUD | 17.73% |
| 2022 Q4 | -10.99 Million AUD | 0.0% |
| 2022 Q2 | -11.82 Million AUD | 0.0% |
| 2021 Q2 | -14.2 Million AUD | 0.0% |
| 2021 Q4 | -13.52 Million AUD | 0.0% |
| 2021 FY | - AUD | -35.17% |
| 2020 Q4 | -11.83 Million AUD | 0.0% |
| 2020 Q2 | -8.68 Million AUD | 0.0% |
| 2020 FY | - AUD | -47.02% |
| 2019 FY | - AUD | -39.92% |
| 2019 Q2 | -7.11 Million AUD | 0.0% |
| 2019 Q4 | -9.99 Million AUD | 0.0% |
| 2018 Q4 | -3.89 Million AUD | 0.0% |
| 2018 FY | - AUD | 33.06% |
| 2018 Q2 | -6.07 Million AUD | 0.0% |
| 2017 Q2 | -7.88 Million AUD | 0.0% |
| 2017 FY | - AUD | 26.82% |
| 2016 FY | - AUD | -14.87% |
| 2016 Q2 | -9.56 Million AUD | 0.0% |
| 2015 Q4 | -9.76 Million AUD | 0.0% |
| 2015 Q2 | -7.96 Million AUD | 0.0% |
| 2015 FY | - AUD | -30.98% |
| 2014 FY | - AUD | -224.51% |
| 2014 Q4 | -8.5 Million AUD | 0.0% |
| 2014 Q2 | -5.02 Million AUD | 0.0% |
| 2013 Q2 | -1.29 Million AUD | 58.52% |
| 2013 Q1 | -3.12 Million AUD | 0.0% |
| 2013 Q3 | -1.04 Million AUD | 19.62% |
| 2013 Q4 | -2.87 Million AUD | -175.59% |
| 2013 FY | - AUD | 66.66% |
| 2012 Q1 | -1.84 Million AUD | 0.0% |
| 2012 FY | - AUD | -69.44% |
| 2012 Q4 | -3.12 Million AUD | 0.0% |
| 2012 Q3 | -3.12 Million AUD | 0.0% |
| 2012 Q2 | -3.12 Million AUD | -69.44% |
| 2011 FY | - AUD | -58.21% |
| 2011 Q3 | -1.84 Million AUD | 0.0% |
| 2011 Q1 | -1.16 Million AUD | 0.0% |
| 2011 Q4 | -1.84 Million AUD | 0.0% |
| 2011 Q2 | -1.84 Million AUD | -58.21% |
| 2010 Q3 | -1.16 Million AUD | 0.0% |
| 2010 FY | - AUD | -105.19% |
| 2010 Q2 | -1.16 Million AUD | -105.19% |
| 2010 Q1 | -568.5 Thousand AUD | 0.0% |
| 2010 Q4 | -1.16 Million AUD | 0.0% |
| 2009 Q2 | -568.5 Thousand AUD | 62.7% |
| 2009 Q3 | -568.5 Thousand AUD | 0.0% |
| 2009 Q4 | -568.5 Thousand AUD | 0.0% |
| 2009 Q1 | -1.52 Million AUD | 0.0% |
| 2009 FY | - AUD | 71.99% |
| 2008 Q2 | -1.52 Million AUD | -3.07% |
| 2008 Q3 | -1.52 Million AUD | 0.0% |
| 2008 FY | - AUD | -2.33% |
| 2008 Q4 | -1.52 Million AUD | 0.0% |
| 2008 Q1 | -1.47 Million AUD | 0.0% |
| 2007 FY | - AUD | -21.43% |
| 2007 Q4 | -1.47 Million AUD | 0.0% |
| 2007 Q1 | -1.63 Million AUD | 0.0% |
| 2007 Q3 | -1.47 Million AUD | 0.0% |
| 2007 Q2 | -1.47 Million AUD | 9.48% |
| 2006 Q1 | -3.61 Million AUD | 0.0% |
| 2006 Q4 | -1.63 Million AUD | 0.0% |
| 2006 Q3 | -1.63 Million AUD | 0.0% |
| 2006 FY | - AUD | 5.08% |
| 2006 Q2 | -1.63 Million AUD | 54.84% |
| 2005 FY | - AUD | -40.98% |
| 2005 Q3 | -3.61 Million AUD | 0.0% |
| 2005 Q4 | -3.61 Million AUD | 0.0% |
| 2005 Q2 | -3.61 Million AUD | -117.93% |
| 2005 Q1 | -1.65 Million AUD | 0.0% |
| 2004 Q4 | -1.65 Million AUD | 0.0% |
| 2004 Q1 | -1.77 Million AUD | 0.0% |
| 2004 Q2 | -1.65 Million AUD | 6.48% |
| 2004 Q3 | -1.65 Million AUD | 0.0% |
| 2004 FY | - AUD | 29.49% |
| 2003 Q2 | -1.77 Million AUD | 8.19% |
| 2003 Q4 | -1.77 Million AUD | 0.0% |
| 2003 Q3 | -1.77 Million AUD | 0.0% |
| 2003 Q1 | -1.93 Million AUD | 0.0% |
| 2003 FY | - AUD | 23.74% |
| 2002 Q4 | -1.93 Million AUD | 0.0% |
| 2002 Q3 | -1.93 Million AUD | 0.0% |
| 2002 Q1 | -1.93 Million AUD | 0.0% |
| 2002 Q2 | -1.93 Million AUD | 0.23% |
| 2002 FY | - AUD | -64.45% |
| 2001 Q1 | -886 Thousand AUD | 0.0% |
| 2001 Q2 | -1.93 Million AUD | -118.7% |
| 2001 Q4 | -1.93 Million AUD | 0.0% |
| 2001 Q3 | -1.93 Million AUD | 0.0% |
| 2001 FY | - AUD | -55.79% |
| 2000 Q2 | -886 Thousand AUD | -51.56% |
| 2000 FY | - AUD | -51.56% |
| 2000 Q4 | -886 Thousand AUD | 0.0% |
| 2000 Q3 | -886 Thousand AUD | 0.0% |
| 2000 Q1 | -584.58 Thousand AUD | 0.0% |
| 1999 FY | - AUD | 8.0% |
| 1999 Q1 | -635.39 Thousand AUD | 0.0% |
| 1999 Q2 | -584.58 Thousand AUD | 8.0% |
| 1999 Q3 | -584.58 Thousand AUD | 0.0% |
| 1999 Q4 | -584.58 Thousand AUD | 0.0% |
| 1998 Q4 | -635.39 Thousand AUD | 0.0% |
| 1998 Q2 | -635.39 Thousand AUD | 0.0% |
| 1998 Q3 | -635.39 Thousand AUD | 0.0% |
| 1998 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AdAlta Limited | -5.3 Million AUD | -137.181% |
| Biome Australia Limited | -1.57 Million AUD | -696.895% |
| Radiopharm Theranostics Limited | -45.37 Million AUD | 72.283% |
| Biotron Limited | -5.04 Million AUD | -149.541% |
| Acrux Limited | -7.93 Million AUD | -58.58% |
| Alterity Therapeutics Limited | -19.57 Million AUD | 35.739% |
| Botanix Pharmaceuticals Limited | -13.91 Million AUD | 9.644% |
| BTC Health Limited | 1.05 Million AUD | 1291.808% |
| Chimeric Therapeutics Limited | -11.29 Million AUD | -11.303% |
| CSL Limited | 4.73 Billion AUD | 100.266% |
| Clarity Pharmaceuticals Ltd | -44.64 Million AUD | 71.831% |
| Clinuvel Pharmaceuticals Limited | 51.86 Million AUD | 124.25% |
| Immutep Limited | -42.87 Million AUD | 70.666% |
| Memphasys Limited | -3.3 Million AUD | -280.232% |
| Neuren Pharmaceuticals Limited | 199.26 Million AUD | 106.312% |
| Noxopharm Limited | -5.94 Million AUD | -111.538% |
| Prescient Therapeutics Limited | -7.18 Million AUD | -75.028% |
| Race Oncology Limited | -14.2 Million AUD | 11.451% |
| Tissue Repair Ltd | -5.77 Million AUD | -117.784% |
| EZZ Life Science Holdings Limited | 10.37 Million AUD | 221.219% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -763.411% |
| Bio-Gene Technology Limited | -2.97 Million AUD | -322.758% |
| Zelira Therapeutics Limited | -36.44 Million AUD | 65.487% |
| Patrys Limited | -3.49 Million AUD | -260.15% |
| Orthocell Limited | -11.68 Million AUD | -7.669% |
| Imugene Limited | -147.97 Million AUD | 91.501% |
| PYC Therapeutics Limited | -38.11 Million AUD | 67.005% |
| Proteomics International Laboratories Limited | -7.88 Million AUD | -59.458% |
| Cynata Therapeutics Limited | -9.95 Million AUD | -26.399% |
| Arovella Therapeutics Limited | -8.83 Million AUD | -42.384% |
| Nanollose Limited | -1.14 Million AUD | -995.652% |
| Invex Therapeutics Ltd | -720.44 Thousand AUD | -1645.736% |
| NeuroScientific Biopharmaceuticals Limited | -1.79 Million AUD | -600.167% |
| Amplia Therapeutics Limited | -4.55 Million AUD | -175.836% |
| Island Pharmaceuticals Limited | -2.81 Million AUD | -346.291% |
| Nyrada Inc. | -4.59 Million AUD | -173.639% |
| Telix Pharmaceuticals Limited | 22.96 Million AUD | 154.764% |
| Dimerix Limited | -24.95 Million AUD | 49.608% |
| PharmAust Limited | -9.45 Million AUD | -33.066% |
| Hexima Limited | -995.54 Thousand AUD | -1163.331% |
| AnteoTech Limited | -11.57 Million AUD | -8.694% |
| Paradigm Biopharmaceuticals Limited | -64.53 Million AUD | 80.513% |
| Recce Pharmaceuticals Ltd | -21.35 Million AUD | 41.103% |
| Avecho Biotechnology Limited | -3.24 Million AUD | -287.879% |
| Actinogen Medical Limited | -12.92 Million AUD | 2.664% |
| Immuron Limited | -6.19 Million AUD | -103.105% |
| Argenica Therapeutics Limited | -1.89 Million AUD | -562.788% |